Nurix Therapeutics, Inc. (NRIX)
22.16
-0.19
(-0.85%)
USD |
NASDAQ |
Oct 12, 16:00
22.52
+0.36
(+1.62%)
After-Hours: 20:00
Nurix Therapeutics Profit Margin (Quarterly) : -990.1% for May 31, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| May 31, 2026 | -990.1% |
| February 28, 2026 | -1.39K% |
| November 30, 2025 | -576.1% |
| August 31, 2025 | -1.09K% |
| May 31, 2025 | -98.66% |
| February 28, 2025 | -305.4% |
| November 30, 2024 | -440.7% |
| August 31, 2024 | -388.9% |
| May 31, 2024 | -368.4% |
| February 29, 2024 | -250.3% |
| November 30, 2023 | -276.8% |
| August 31, 2023 | -200.3% |
| May 31, 2023 | -79.14% |
| February 28, 2023 | -321.1% |
| November 30, 2022 | -688.7% |
| Date | Value |
|---|---|
| August 31, 2022 | -423.6% |
| May 31, 2022 | -397.1% |
| February 28, 2022 | -442.1% |
| November 30, 2021 | -509.8% |
| August 31, 2021 | -281.3% |
| May 31, 2021 | -372.0% |
| February 28, 2021 | -484.4% |
| November 30, 2020 | -297.7% |
| August 31, 2020 | -453.3% |
| May 31, 2020 | |
| February 29, 2020 | -432.6% |
| November 30, 2019 | -726.0% |
| August 31, 2019 | -22.94% |
| May 31, 2019 | -32.50% |
| February 28, 2019 | -29.08% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -134.2% |
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
| Savara, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -76.12% |
| Return on Assets | -57.12% |
| Return on Invested Capital | -67.65% |
| Gross Profit Margin (Quarterly) | 57.43% |
| Operating Margin (Quarterly) | -1.04K% |
| Return on Net Operating Assets | -451.5% |